Research News and Research

RSS

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.

23 Nov 2009

Asterand extends its collaboration agreement with Bristol-Myers Squibb

Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.

23 Nov 2009

AdnaTest BreastCancer Select & Detect kit now available in the Czech Republic and Slovakia

OncoVista Innovative Therapies, Inc., reported that the AdnaTest BreastCancer Select & Detect kit, manufactured by AdnaGen AG (Langenhagen, Germany), is now available for research as well as for pay-out-of-pocket patients in the Czech Republic and Slovakia.

23 Nov 2009

Zynx Health partners with Healthcare Solutions Division of Keane for EHR integration

Zynx Health, the market leader in providing evidence-based and experience-based clinical decision support solutions, today announced its partnership with the Healthcare Solutions Division of Keane, Inc., allowing the integration of Zynx Health solutions with Keane’s OptimumTM electronic health records (EHR) system.

23 Nov 2009

Nevada Cancer Institute selects Sprint as its wireless communications provider at its new Las Vegas facility

Nevada Cancer Institute has selected Sprint as its wireless communications provider of choice at its new, state-of-the-art facility near Las Vegas. This is the first Sprint in-building coverage and capacity agreement involving a large healthcare institution in the Las Vegas market.

23 Nov 2009

Receptos raises $25 million through Series A financing

Receptos, Inc., a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing. The company is focused on identifying and developing best- and first-in-class GPCR therapeutic candidates through information-driven drug discovery, including GPCR structure. Investors include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.

23 Nov 2009

Bio-Quant to be acquired by NexMed

NexMed, Inc., a developer of products based on the NexACT® technology, today announced that it has entered into a definitive agreement to acquire Bio-Quant, Inc., a revenue generating privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.

23 Nov 2009

MMR Information Systems to add new feature in its personal health record website

MMR Information Systems, Inc. announced today it will add a clinical trials information service to its MyMedicalRecords Personal Health Record site, www.mymedicalrecords.com.

23 Nov 2009

Lannett CEO to participate in NYSE opening bell ringing ceremony

Lannett Company, Inc. (NYSE AMEX: LCI) today announced that President and Chief Executive Officer Arthur Bedrosian will ring the opening bell at the New York Stock Exchange at 9:30 a.m. Eastern on Monday, November 23, 2009.

23 Nov 2009

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

ARIAD Pharmaceuticals, Inc. today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009.

23 Nov 2009

Nightingale Informatix announces financial results for the quarter and six months ended September 30, 2009

Nightingale Informatix Corporation, an application service provider (ASP) of electronic medical record (EMR) software and related services announces its financial results for the quarter and six months ended September 30, 2009. All results are reported in Canadian dollars unless otherwise stated.

23 Nov 2009

Kingston University receives £99,000 for cancer research

Scientists have begun a three-year study to analyse why cancer patients become resistant to treatments designed to fight the disease. A research team from Kingston University has been awarded £99,000 to investigate why some tumours are sensitive and respond to treatments and why other tumours do not.

23 Nov 2009

First Edition: November 23, 2009

Today's headlines indicate that even after Senate Majority Leader Harry Reid found victory Saturday night with the first health bill test vote, his measure is likely to be the subject of an even more intense debate as the measure moves forward.

23 Nov 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

Three-day interactive conference to showcase new trendsetting techniques and research in aesthetic plastic surgery

Aesthetic Plastic Surgery: The Next Generation Symposium will be held from December 4-6 at the Waldorf Astoria, announces Z. Paul Lorenc, MD, FACS, New York aesthetic plastic surgeon and Chairman of the APSSNY.

23 Nov 2009

Cellular prion protein and epileptic seizures: researchers find new role

Cellular prion protein (PrPc) plays an essential role in maintaining neurotransmitter homeostasis in the central nervous system. This discovery has been made possible by the observation that both a deficiency and an excess of the protein have a considerable effect on this homeostasis.

23 Nov 2009

MedPro Safety Products updates on its recent progress

MedPro Safety Products, Inc., a pioneer in the development and marketing of passive needlestick injury prevention technology, today reported on the Company’s recent progress.

23 Nov 2009

STD infections continue to rise among young people

Sexually spread diseases continue to rise, with reported chlamydia cases setting yet another record in 2008, officials at the Centers for Disease Control recently reported. The CDC estimates that approximately 19 million new STD infections occur each year. Approximately half of them occur in young people between 15 to 24 years of age.

23 Nov 2009

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.

23 Nov 2009

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.

23 Nov 2009

Research News and Research

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Asterand extends its collaboration agreement with Bristol-Myers Squibb

AdnaTest BreastCancer Select & Detect kit now available in the Czech Republic and Slovakia

Zynx Health partners with Healthcare Solutions Division of Keane for EHR integration

Nevada Cancer Institute selects Sprint as its wireless communications provider at its new Las Vegas facility

Receptos raises $25 million through Series A financing

Bio-Quant to be acquired by NexMed

MMR Information Systems to add new feature in its personal health record website

Lannett CEO to participate in NYSE opening bell ringing ceremony

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

Nightingale Informatix announces financial results for the quarter and six months ended September 30, 2009

Kingston University receives £99,000 for cancer research

First Edition: November 23, 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Three-day interactive conference to showcase new trendsetting techniques and research in aesthetic plastic surgery

Cellular prion protein and epileptic seizures: researchers find new role

MedPro Safety Products updates on its recent progress

STD infections continue to rise among young people

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical announces results of NGX426 clinical trial

Spectroscopy Applications in the Environment eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring